Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $13.7252W HIGH $27.30
Volume
1.64 M
Value Traded
79.96 M
Short % Float
14.87%
+12.24%Week
-11.1%1 Month
-27.16%3 Month
-8.67%6 Month
-3.93%5 Year
-23.11%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.18 B
EPS (TTM)
-2.78
P/E Ratio
-
Ent. Value
2.48 B
Total Shares
186.77 M
Float Shares
157.22 M
Insiders
15.81%
Institutions
85.19%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
DYN Catalyst Timeline
Dated clinical, regulatory and corporate events for Dyne Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dyne Therapeutics, Inc.
312Total events
29Upcoming
60Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Poster Presentationz-basivarsenPresentation
Poster presentation at AANEM available September 30, 2026
Myotonic Dystrophy Type 1 (DM1)source ↗
▲Oral Presentationz-basivarsenPresentation
Oral presentation of long-term functional improvement data at WMS
Myotonic Dystrophy Type 1 (DM1)source ↗
◆Timing Guidancezeleciment basivarsenPresentation
Disclosure of mean baseline video hand opening time (vHOT) in ACHIEVE registrational expansion cohort
Myotonic Dystrophy Type 1 (DM1)source ↗
▲IND ClearanceDYNE-302IND
FDA clearance of IND for DYNE-302
facioscapulohumeral muscular dystrophy (FSHD)source ↗
◆Trial InitiationDYNE-302Trial
Initiation of Phase 1 clinical trial for DYNE-302 in FSHD
facioscapulohumeral muscular dystrophy (FSHD)source ↗
▲BLA Submissionz-rostudirsenFiledRegulatory Filing
BLA submission for z-rostudirsen accepted by FDA
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
▲FDA Filing Acceptedz-rostudirsenFiledRegulatory Filing
FDA accepted BLA for z-rostudirsen with Priority Review
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
▲Priority Reviewz-rostudirsenFiledRegulatory Filing
Priority Review granted for z-rostudirsen BLA
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
▲Primary Endpoint Metz-rostudirsenFiledClinical Data
Registrational expansion cohort met primary endpoint (dystrophin increase)
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
▲FDA Filing Acceptedz-rostudirsenFiledRegulatory Filing
FDA accepted BLA for z-rostudirsen with Priority Review
DMD amenable to exon 51 skippingsource ↗
▲Priority Reviewz-rostudirsenFiledRegulatory Filing
FDA granted Priority Review for z-rostudirsen BLA
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
▲Trial Initiationz-basivarsenTrial
Began dosing in global confirmatory Phase 3 HARMONIA trial
DM1source ↗
▼Equity OfferingCorporate
Completed underwritten public offering of 21,045,000 shares at $20.50 per share
▲Debt Royalty FinancingCorporate
Expanded debt facility of up to $400 million with Hercules Capital; $50 million funded at closing
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference 2026 meetings
▲Enrollment Completezeleciment basivarsenTrial
Completion of enrollment in registrational expansion cohort of ACHIEVE trial
myotonic dystrophy type 1 (DM1)source ↗
▲Enrollment Completez-basivarsenTrial
Completed enrollment of 71 participants in ACHIEVE REC
DM1source ↗
●Debt Royalty FinancingCorporate
Expanded debt facility with Hercules Capital to up to $400 million
◆Oral PresentationPresentation
2026 RBC Capital Markets Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Oral presentation on robust and widespread MAPT silencing in CNS of mice and NHP with TfR1-mediated oligonucleotide delivery
Tauopathiessource ↗
▲Pre BLA Meetingz-rostudirsenFiledFDA Meeting
Positive pre-BLA meeting completed with FDA for z-rostudirsen
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
▲Trial Initiationz-rostudirsenFiledTrial
Initiated global confirmatory Phase 3 FORZETTO trial
DMD amenable to exon 51 skippingsource ↗
◆Enrollment Completezeleciment basivarsenTrial
Complete enrollment in ACHIEVE Registrational Expansion Cohort
myotonic dystrophy type 1source ↗
◆Timing Guidancezeleciment rostudirsenPresentation
Submission for U.S. Accelerated Approval on track for Q2 2026
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
◆Timing Guidancez-rostudirsenFiledPresentation
Planned BLA submission for U.S. Accelerated Approval of z-rostudirsen
Duchenne muscular dystrophy (exon 51 skip amenable)source ↗
◆Trial Initiationz-rostudirsenFiledTrial
Initiation of global confirmatory Phase 3 trial of z-rostudirsen
Duchenne muscular dystrophy (exon 51 skip amenable)source ↗
▲Enrollment Completez-basivarsenTrial
Enrollment target of 60 participants reached in ACHIEVE REC; completion expected in Q2 2026
Myotonic dystrophy type 1 (DM1)source ↗
◆Oral Presentationz-basivarsenPresentation
Presentation of HARMONIA trial design at 2026 MDA Clinical & Scientific Conference
myotonic dystrophy type 1 (DM1)source ↗
◆Poster Presentationz-basivarsenPresentation
Poster on HARMONIA trial design available at MDA conference
myotonic dystrophy type 1 (DM1)source ↗
▲Trial Initiationz-basivarsenTrial
Initiation of Phase 3 HARMONIA trial of z-basivarsen in DM1
myotonic dystrophy type 1 (DM1)source ↗
▲Late-Breakerzeleciment rostudirsenPresentation
Late-breaking poster presentation of additional cardiopulmonary data from DELIVER trial at MDA Conference
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
▲Poster Presentationzeleciment rostudirsenPresentation
Poster presentation titled 'Zeleciment rostudirsen led to trends in long-term improvement in clinical outcomes including cardiopulmonary function: Additional data from DELIVER'
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
◆Oral Presentationz-rostudirsenFiledPresentation
Presentation of long-term data from DELIVER trial at MDA Clinical & Scientific Conference
Duchenne muscular dystrophy (exon 51 skip amenable)source ↗
◆Oral Presentationz-basivarsenPresentation
Presentation of Phase 3 trial design for z-basivarsen at MDA Clinical & Scientific Conference
Myotonic dystrophy type 1source ↗
▲Oral Presentationz-rostudirsenFiledPresentation
Positive cardiopulmonary results and long-term dystrophin data presented at MDA 2026
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
◆Trial Initiationz-basivarsenTrial
Initiation of global confirmatory Phase 3 trial of z-basivarsen
Myotonic dystrophy type 1source ↗
▲EU Orphan Designationzeleciment basivarsenEx-US Regulatory
Orphan Drug Designation in Japan for zeleciment basivarsen
myotonic dystrophy type 1source ↗
◆Timing GuidanceDYNE-251Presentation
Potential BLA submission for U.S. accelerated approval anticipated
Duchenne muscular dystrophy (DMD) amenable to exon 51 skippingsource ↗
◆Topline ReadoutDYNE-101FiledClinical Data
Data from Registrational Expansion Cohort of ACHIEVE trial planned
myotonic dystrophy type 1 (DM1)source ↗
◆Trial InitiationDYNE-101FiledTrial
Plan to initiate confirmatory Phase 3 clinical trial for DYNE-101
Myotonic Dystrophy Type 1 (DM1)source ↗
◆Timing GuidanceDYNE-101FiledPresentation
Potential BLA submission for U.S. Accelerated Approval for DYNE-101
myotonic dystrophy type 1 (DM1)source ↗
▲Quarterly UpdateCorporate
Cash position of ~$1.1 billion as of 12/31/25 with expected runway into Q1 2028
▼Equity OfferingCorporate
Pricing of upsized $350M public offering of common stock at $18.44 per share
Past FDA Catalysts and PDUFA Decisions
How DYN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | zeleciment basivarsen (z-basivarsen, DYNE-101) | Phase 1/2 data presentation | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$24M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 39%
Small Cap(rank 257 of 658)
Percentile Rank
Dyne Therapeutics, Inc. carries a moderate pipeline score (40/100), with $37M risk-adjusted pipeline value, led by Zeleciment rostudirsen in Duchenne Muscular Dystrophy (DMD) (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Zeleciment rostudirsen RNA therapyNCT05524883 | Duchenne Muscular Dystrophy (DMD) | Phase 3 | ACTIVE NOT_RECRUITING | 176 | Sep 1, 2031 |
Clinical Trial Results
Readouts, endpoints and source filings for every DYN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| z-basivarsen BreakthroughFast TrackOrphan | myotonic dystrophy type 1 (DM1) | Phase 1/2 | 2026-09-29 | mean baseline vHOT in the ACHIEVE REC is 8.3 seconds; functional improvement across multiple measures compared to baseline, versus placebo and versus a matched natural history cohortRead More | Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Posner Brian SDirector | Buy | 2,500 27,000 held | $16.00 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DYN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 2.5 % (4.2 %) | 102.50 M | 4.62 M |
DYN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DYN ranks across every disease it competes in
Competitive Position is a premium feature
See how DYN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDYN News
DYNDyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics has released additional one-year clinical data from its Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1). The data indicate significant functional improvements across various measures compared to baseline and placebo. Dyne anticipates topline results from the registrational expansion cohort in Q1 2027, aiming for U.S. Accelerated Approval by Q3 2027.
Read more →DYN▼ -5.3%on this news
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics has announced the granting of inducement equity awards to 14 new employees as part of their hiring process. The awards include stock options and restricted stock units, aimed at encouraging acceptance of employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and demonstrates the company's commitment to growth and talent acquisition.
Read more →DYN▼ -16.4%on this news
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
Dyne Therapeutics announced it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of z-basivarsen for myotonic dystrophy type 1 (DM1) at two upcoming medical meetings. The presentations will include data from a pooled dose group and safety updates. Topline data from the registrational expansion cohort is anticipated in Q1 2027.
Read more →DYNDyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
Dyne Therapeutics announced the presentation of preclinical data for four investigational therapies targeting Duchenne Muscular Dystrophy (DMD) at the upcoming NMSG Scientific Meeting. The therapies, DYNE-253, DYNE-245, DYNE-244, and DYNE-255, aim to address specific exon mutations and are advancing into IND-enabling studies. The data supports the effectiveness of the FORCE™ platform in delivering therapeutic payloads.
Read more →DYNDyne Therapeutics to Participate in Upcoming Investor Conferences
Dyne Therapeutics has announced its participation in several upcoming investor conferences, including the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and Baird Global Healthcare Conference. These events will feature fireside chats with management, aimed at discussing the company's advancements in therapeutics for genetically driven neuromuscular diseases. Webcasts of the chats will be available on the company's website.
Read more →DYNDyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics reported its Q2 2026 financial results, highlighting significant progress in its clinical programs. The FDA accepted the Biologics License Application for z-rostudirsen, granting Priority Review with a target action date set for January 2027. Additionally, the company completed enrollment in the Phase 1/2 ACHIEVE trial for z-basivarsen and received IND clearance for DYNE-302. Despite a net loss increase, Dyne expects to maintain a strong cash runway into Q2 2028.
Read more →DYNDyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Dyne Therapeutics has received FDA clearance for its IND application to initiate a Phase 1 clinical trial for DYNE-302, targeting facioscapulohumeral muscular dystrophy (FSHD). This investigational drug aims to suppress DUX4 expression, which is implicated in FSHD pathogenesis. The trial will primarily assess safety and tolerability, with additional evaluations of pharmacokinetics and pharmacodynamics.
Read more →DYNDyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dyne Therapeutics has successfully closed an upsized public offering of 21,045,000 shares at $20.50 each, raising approximately $431.4 million. The offering included an additional 2,745,000 shares purchased by underwriters. This funding will support Dyne's mission to develop therapies for genetically driven neuromuscular diseases.
Read more →DYNDyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
Dyne Therapeutics has announced the pricing of an upsized public offering of 18.3 million shares at $20.50 each, aiming to raise approximately $375 million. The offering is expected to close around July 23, 2026, pending customary conditions. Dyne is focused on developing therapies for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy.
Read more →DYNDyne Therapeutics Announces Proposed Public Offering of Common Stock
Dyne Therapeutics has announced a proposed public offering of $300 million in common stock, with an additional $45 million option for underwriters. The offering aims to support its clinical programs targeting genetically driven neuromuscular diseases. Market conditions may impact the completion and terms of the offering.
Read more →DYNDyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics announced that the FDA has accepted its Biologics License Application for z-rostudirsen, aimed at treating Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The application has been granted Priority Review, with a target action date set for January 21, 2027. The treatment showed significant improvements in dystrophin production and functional outcomes in clinical trials.
Read more →DYNDyne Therapeutics Appoints Barry Greene to Board of Directors
Dyne Therapeutics has appointed Barry Greene to its Board of Directors as part of its strategy to transition into a commercial biotechnology company. Greene brings over 30 years of experience in the biopharmaceutical industry, which includes leadership roles at Sage Therapeutics and Alnylam Pharmaceuticals. His expertise is expected to enhance Dyne's capabilities in delivering innovative therapies for neuromuscular diseases.
Read more →DYN▲ +6.3%on this newsshared move
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
Dyne Therapeutics has expanded its debt facility with Hercules Capital, increasing its borrowing capacity by up to $400 million. This amendment includes an immediate funding of $50 million and additional funds contingent on achieving specific milestones. The company aims to leverage this capital to advance its clinical programs for Duchenne muscular dystrophy and myotonic dystrophy, with potential U.S. launches in the next two years.
Read more →DYNDyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics announced the completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE trial for z-basivarsen, targeting myotonic dystrophy type 1 (DM1). A total of 71 participants were enrolled, with topline data expected in Q1 2027. The company aims for a potential U.S. launch in H1 2028, pending FDA approval.
Read more →DYNDyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
Read more →DYNDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 20, 2026
Dyne Therapeutics has granted inducement equity awards to 17 new employees as part of their hiring process, in compliance with Nasdaq Listing Rule 5635(c)(4). The awards include stock options and restricted stock units, which are designed to incentivize long-term commitment to the company. Dyne is dedicated to developing therapies for genetically driven neuromuscular diseases.
Read more →DYN▲ +10.3%on this newsshared move
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
Read more →About Dyne Therapeutics, Inc.
Headquarters1560 TRAPELO ROAD, WALTHAM, MA, 02451
BIOPHARMAWATCH ELITE PLUS
Trade the next DYN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime